Why BGPT?
logo

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.

Press Enter ↡ to search evidence



    Explore by Goal












     Long Response


    Ras codon-focused graphs (KRAS vs NRAS; codons 12 vs 61)
    Your request says β€œcodon bias”, but the provided research data does not contain genome-wide synonymous-codon-usage (tRNA/translation) measurements. Instead, it contains codon-level mutation distributions (e.g., KRAS G12* vs KRAS Q61*) in specific cohorts. So the graphs below are mutation-codon enrichment for KRAS at codons 12 and 61, derived only from the included datasets.
    Graph 1 β€” Human metastatic CRC cohort: KRAS codon 12 vs 61 counts
    Source cohort (n=100 metastatic CRC patients resistant to EGFR-targeted therapy): KRAS mutations were reported by codon as codon 12: 36, codon 13: 2, codon 61: 8, codon 117: 2, codon 146: 2 (total KRAS-mutated cases: 48).
    Graph 2 β€” Mouse hemangiosarcoma model: KRAS codon 12 vs 61 mutation counts by exposure
    In B6C3F1 mouse hemangiosarcomas:
    • riddelliine group (n=12 hemangiosarcomas): K-ras codon 12 mutations were reported as 7.
    • o-nitrotoluene group (n=15): K-ras codon 61 mutation was reported as 1.
    • spontaneous controls (n=15): no K-ras/p53/beta-catenin mutations were reported.
    Graph 3 β€” Human CRC cohort context (codon-level mutation spectra in colorectal cancer)
    Another included colorectal-cancer computational analysis reports multiple KRAS G12 substitutions (codon 12/13 region) and indicates codon-12–dominant patterns (e.g., G12D, G12V, G12C) and cancer-context differences (MSS vs MSI/hypermutated), but it does not provide codon 61 counts in the provided extracted fields. Therefore, it cannot be used to build a faithful codon-12 vs codon-61 KRAS-vs-NRAS plot without additional codon-61 mutation counts.
    KRAS vs NRAS and β€œcodon bias”: what the current evidence can and cannot support
    • Supported by the provided raw extracts: KRAS codon 12 mutations are more frequent than KRAS codon 61 mutations in the included human metastatic CRC cohort resistant to EGFR therapy (36 vs 8 cases).
    • Not supported / missing in the provided extracts: any NRAS codon-12 vs codon-61 quantitative distribution for the requested comparison. The extracted metastatic CRC text reports NRAS mutations in only 1 patient but does not specify the codon for that single NRAS mutation.
    • β€œCodon bias” mechanism caution: mutation distributions at codons 12/61 are not the same as synonymous codon usage bias for translation. The supplied papers do not contain codon-usage (synonymous) metrics; so a mechanistic β€œcodon bias” claim would be an overreach beyond the available data.
    • Model limitations: the mouse model data involve different exposures and small n per group, and the human data are from a therapy-resistant subsetβ€”both can shift mutation spectra relative to general population tumors.
    Follow-up BGPT actions (to fully answer β€œKRAS vs NRAS codon 12 vs 61”)
    If you want a complete KRAS-vs-NRAS codon-12 vs codon-61 plot, we need datasets that explicitly quantify NRAS codon 12 and NRAS codon 61 (or codon-level mutation tables) from the provided sources.


    Feedback:    

    Updated: April 19, 2026

     Top Data Sources ExportMCP


     Analysis Wizard



    It will extract codon-level mutation counts for KRAS and NRAS at codons 12 and 61 from all provided sources, reconcile cohort-specific denominators, and output Plotly-ready frequency tables and KRAS-vs-NRAS codon graphs.



     Science Art


    Create Graphs: Ras codon bias KRAS vs NRAS codons 12 vs 61 Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending